Since the first ATH434 ( =PBT434) in 2017 by Finkelstein et al only 6 papers have been published: 3 in experimental PD, 2 in experimental MSA, and one about the endothelium. Not a single one this year, 2 in 2022 and 3 in 2021. There have been some congress abstracts, however.
Publications are not the main issue, but in the annual reports we have been told that a lot of research has been done, and with the invention of new patented molecules positive results have been claimed. Most likely much of the money has been spent on these preclinical studies but we have not been informed of any of that dealing with the molecules of ATH.
No publication "rule" also applies with PBT2 after spring 2022 with one exception, the gonorrhea paper in September 2022. No info about the commercialization project for almost 3 years.
This company needs positive news to survive. I believe that they have them because they are so happy with the progress but they have not told them to us.
ATH Price at posting:
0.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)